BROOMFIELD, Colo.--(BUSINESS WIRE)--ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for atrial fibrillation, heart failure and other cardiovascular diseases, today announced that the editorial “Treatment of the Heart Failure Patient with Atrial Fibrillation: A Major Unmet Need” was published in the first edition of JACC: Heart Failure, a new journal of the American College of Cardiology (http://heartfailure.onlinejacc.org/article.aspx?articleid=1568319). The editorial, authored by ARCA’s President and Chief Executive Officer, Dr. Michael Bristow, and Dr. Ryan Aleong of the University of Colorado, discusses the authors’ views that the treatment of atrial fibrillation (“AF”) in heart failure (“HF”) patients with reduced left ventricular ejection fractions (“HFREF”) is a major unmet need in cardiovascular therapies and should be approached differently from current treatments for HFREF patients with sinus rhythm.
